Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
NCT01579994
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
13
Enrollment
OTHER
Sponsor class
Conditions
Advanced Lung Cancer
Interventions
DRUG:
Ganetespib (STA-9090) and crizotinib
Sponsor
Memorial Sloan Kettering Cancer Center